Biotech Catalyst & Software Earnings Finale

Markets are entering the final stretch of pre-FOMC positioning, with Salesforce and Snowflake set to report tonight and the high-impact ASH Biotech Conference just days away. Today’s trading hinges on crucial macro data (ADP, ISM) that could confirm—or challenge—the market’s…

Biotech Catalyst Watch: Kura Oncology (KURA) Ahead of ASH

Kura remains a High-Conviction Buy heading into its December 8 data presentation at the American Society of Hematology (ASH)—a potential inflection point for sentiment and valuation.

Product & Market PositioningKura’s Ziftomenib, already FDA-approved for relapsed/refractory NPM1-mutated AML, is moving toward the much larger $3B–$7B front-line AML market.

Competitive EdgeZiftomenib avoids the QTc prolongation boxed warning that weighs on rival treatment Revuforj (Syndax), creating a meaningful safety advantage.

Catalyst to WatchPhase 1b KOMET-007 results on December 8 will determine how it stacks against Syndax’s strong efficacy data. Expect volatility—the readout is pivotal for long-term competitiveness.

Investor TakeawayPosition for catalyst-driven movement. Kura’s partnership with Kyowa Kirin helps de-risk the financial path, but data strength will dictate upside.Price: $11.14 | Target: $13

Software Earnings Finale: Salesforce & Snowflake Take Center Stage

Tonight marks the last major enterprise software earnings of the year, with Salesforce and Snowflake poised to shape expectations for FY2026 IT spending.

Key Metrics to Watch

Salesforce: AI adoption signals (Agentforce ARR, margin expansion, enterprise deal size).
Snowflake: A potential third consecutive guidance raise, reinforcing the AI data-consumption thesis.

Investor TakeawayFocus on companies with tangible AI monetization, not distant promises. Strong guidance and accelerating AI-driven workloads remain the performance differentiator.

Macro Focus: ADP Jobs Report Takes on Outsize Importance

With official jobs data delayed until December 16, this morning’s ADP private payrolls, ISM services, and final PMIs carry unusual pre-FOMC weight.

Market Implications

Resilient hiring supports the case for a controlled slowdown—aligning with the expected rate cut.
Significant weakness could push markets to price in even more dovish Fed action.

Investor TakeawayADP has more influence than usual this week. Expect a directional market reaction within minutes of the release.

Bitcoin’s Rebound Signals Risk-On Appetite Returning

Bitcoin has surged ~7.4% over the past 24 hours to $92,893, partially reversing last week’s pullback and sending a strong signal about market risk appetite.

Why It MattersCrypto strength has recently correlated with broader risk-on behavior among institutional and retail traders.

Investor TakeawaySustained momentum above $90K supports positioning toward growth equities and higher-beta tech.

Retail Earnings Show Consumer Still Holding Up

Retail earnings (American Eagle, Macy’s, Dollar Tree) are offering a final read on consumer strength heading into peak holiday spending.

Key Data Points

American Eagle jumped 10% on stronger-than-expected Q3 results and significantly upgraded Q4 comparable-sales guidance.
Dollar stores continue to signal stress levels among lower-income shoppers.

Investor TakeawayRobust retail execution supports the soft-landing thesis, reinforcing broader market stability through year-end.

Sources:

Market Munchies and Mode Mobile communications are for informational purposes only, and are not a recommendation, solicitation, or research report relating to any investment strategy, security, or digital asset. All investments involve risk including the loss of principal and past performance does not guarantee future results.

Any information contained in this commentary does not purport to be a complete description of the securities, markets, or developments referred to in this material. The information has been obtained from sources considered to be reliable, but we do not guarantee that the foregoing material is accurate or complete. There is no guarantee that any statements or opinions provided herein will prove to be correct.